智通财经APP获悉，康宁杰瑞制药-B(09966)涨超4%，截至发稿，涨4.32%，报9.18港元，成交额811.35万港元。
消息面上，5月22日，康宁杰瑞生物制药宣布，恩维达®（恩沃利单抗注射液，康宁杰瑞研发代号：KN035）新辅助/辅助治疗可切除非小细胞肺癌（NSCLC）的Ⅲ期临床研究（研究编号：KN035-CN-017），已完成全部患者入组。这一里程碑标志着恩维达®在早期肺癌围手术期治疗领域取得重要进展，有望为肺癌患者带来更便捷、更安全的皮下免疫治疗新方案。
目前恩维达®还有多个临床研究在进行中，进一步拓展适应症。联合吉西他滨和奥沙利铂（GEMOX）方案用于一线治疗不可切除或转移性胆道癌适应症的新药上市申请已获国家药品监督管理局（NMPA）受理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.